June 22, 2013

Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300

EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus®

Topline results of EDITION II consistent with EDITION I findings

 

Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
EDITION I demonstrated similar blood sugar control with fewer night-time low blood sugar events compared to Lantus®

Paris, France – June 22, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.